Biogen - Largest Companies by Marketcap, Revenue, Net Income and Employees
Top Corporates Hub
Biogen
BIIB
|
NASDAQ
|
United States
865
-305
Rank
$32.85B
Market Cap
$9.67B
-$ 0.16B
-1.63%
Revenue
$1.90B
+$ 0.61B
+47.29%
Earnings
7.6K
+0K
+0.46%
Employees
About
Biogen, Inc. (BIIB)
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
- Sector: Health Technology
- Industry: Pharmaceuticals: Major
- Headquarters:
Latest News
-
The Bull Case For Biogen (BIIB) Could Change Following New QALSODY ALS Data And Nasdaq-100 Exit - Learn Why
23.12.2025 -
Biogen (BIIB): Reassessing Valuation After a Recent 3-Month Share Price Rebound
18.12.2025 -
Analysts flag risks for Strategy at Nasdaq 100 index reshuffle
12.12.2025 -
Why Analysts See Biogen’s Story Shifting Toward Undervalued Growth Potential
11.12.2025 -
Does Biogen’s Recent Share Price Rebound Reflect Its True Value in 2025?
11.12.2025